SCHEMBL6038563

SCHEMBL6038563

Cc1ccc(S(=O)(=O)Nc2nccnc2OCc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.54
CDK1 P06493 1/20 0.54
CCNB1 P14635 1/20 0.54
CCNA2 P20248 1/20 0.54
CDK2 P24941 1/20 0.54
CDK7 P50613 1/20 0.54
CCNH P51946 1/20 0.54
CCNA1 P78396 1/20 0.54
FFAR4 Q5NUL3 1/20 0.54
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
XBP1 P17861 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039217 0.88 MEN1 (0.51) FFAR1CDK1CCNB1CCNA2CDK2
SCHEMBL6038725 0.87 KMT2A (0.48) MEN1KMT2ATDP1LMNATP53
SCHEMBL6039056 0.85 CCR4 (0.58) FFAR1CDK1CCNB1CCNA2CDK2
SCHEMBL6038703 0.84 KMT2A (0.54) MEN1KMT2ATDP1LMNAPOLB
SCHEMBL6039011 0.84 KMT2A (0.47) MEN1KMT2APOLBARADAMTS4
SCHEMBL6039144 0.84 AR (0.60) MEN1KMT2ALMNAMAPTALOX12
SCHEMBL6038504 0.83 MEN1 (0.50) MEN1KMT2ATDP1LMNATP53
SCHEMBL6038518 0.82 CCR4 (0.46) MEN1KMT2ATDP1LMNAMAPT
SCHEMBL6038899 0.82 F2 (0.47) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6038605 0.82 KMT2A (0.54) MEN1KMT2ALMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 FFAR1 290/4885CDK1 2022/4885CCNB1 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.